JP2019525764A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019525764A5 JP2019525764A5 JP2019504782A JP2019504782A JP2019525764A5 JP 2019525764 A5 JP2019525764 A5 JP 2019525764A5 JP 2019504782 A JP2019504782 A JP 2019504782A JP 2019504782 A JP2019504782 A JP 2019504782A JP 2019525764 A5 JP2019525764 A5 JP 2019525764A5
- Authority
- JP
- Japan
- Prior art keywords
- substitution
- factor
- replaced
- nucleic acid
- acid molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000006467 substitution reaction Methods 0.000 claims 22
- 102100022641 Coagulation factor IX Human genes 0.000 claims 19
- 108010076282 Factor IX Proteins 0.000 claims 17
- 229960004222 factor ix Drugs 0.000 claims 17
- 108020004707 nucleic acids Proteins 0.000 claims 11
- 150000007523 nucleic acids Chemical class 0.000 claims 11
- 102000039446 nucleic acids Human genes 0.000 claims 11
- 239000013598 vector Substances 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 208000009429 hemophilia B Diseases 0.000 claims 2
- 230000023597 hemostasis Effects 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 241000701161 unidentified adenovirus Species 0.000 claims 2
- 108090000317 Chymotrypsin Proteins 0.000 claims 1
- 108010048049 Factor IXa Proteins 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 229960002376 chymotrypsin Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002439 hemostatic effect Effects 0.000 claims 1
- 229960000027 human factor ix Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662367321P | 2016-07-27 | 2016-07-27 | |
| US62/367,321 | 2016-07-27 | ||
| PCT/US2017/044104 WO2018022844A2 (en) | 2016-07-27 | 2017-07-27 | Compositions and methods for modulating factor ix function |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019525764A JP2019525764A (ja) | 2019-09-12 |
| JP2019525764A5 true JP2019525764A5 (enExample) | 2020-09-03 |
| JP7181855B2 JP7181855B2 (ja) | 2022-12-01 |
Family
ID=61016739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019504782A Active JP7181855B2 (ja) | 2016-07-27 | 2017-07-27 | 第ｉｘ因子の機能を調節するための組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11708570B2 (enExample) |
| EP (2) | EP4566666A3 (enExample) |
| JP (1) | JP7181855B2 (enExample) |
| CN (1) | CN109789181A (enExample) |
| CA (1) | CA3034566A1 (enExample) |
| WO (1) | WO2018022844A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
| GB201813528D0 (en) | 2018-08-20 | 2018-10-03 | Ucl Business Plc | Factor IX encoding nucleotides |
| WO2020187969A1 (en) * | 2019-03-19 | 2020-09-24 | CSL Behring Lengnau AG | Factor ix variants and uses thereof in therapy |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2008006313A (es) | 2005-11-15 | 2008-11-06 | Philadelphia Children Hospital | Metodos y composiciones para modular la hemostasia. |
| BRPI0712008A2 (pt) * | 2006-05-24 | 2012-01-10 | Novo Nordisk Healthcare Ag | derivados e análogos de fix prolongados |
| TW200804416A (en) * | 2006-06-19 | 2008-01-16 | Nautilus Technology Llc | Modified coagulation factor IX polypeptides and use thereof for treatment |
| US7968683B1 (en) | 2008-05-07 | 2011-06-28 | Schering Corporation | Factor IXa crystals, related complexes and methods |
| CA2769258A1 (en) | 2009-07-31 | 2011-02-03 | Bayer Healthcare Llc | Modified factor ix polypeptides and uses thereof |
| TWI595004B (zh) * | 2010-11-03 | 2017-08-11 | 介控生化科技公司 | 經修飾之第九因子多胜肽及其用途 |
| EP2760887B1 (en) | 2011-09-30 | 2024-10-23 | The Children's Hospital of Philadelphia | Compositions and methods for modulating hemostasis |
| US10676731B2 (en) | 2014-08-19 | 2020-06-09 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating factor IX function |
-
2017
- 2017-07-27 US US16/320,137 patent/US11708570B2/en active Active
- 2017-07-27 CN CN201780059441.0A patent/CN109789181A/zh active Pending
- 2017-07-27 JP JP2019504782A patent/JP7181855B2/ja active Active
- 2017-07-27 CA CA3034566A patent/CA3034566A1/en active Pending
- 2017-07-27 EP EP25157940.5A patent/EP4566666A3/en active Pending
- 2017-07-27 WO PCT/US2017/044104 patent/WO2018022844A2/en not_active Ceased
- 2017-07-27 EP EP17835248.0A patent/EP3490586B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102569204B1 (ko) | B형 간염 바이러스 감염에 대한 치료 백신접종을 위한 합성 롱 펩티드(slp) | |
| JP2018506286A5 (enExample) | ||
| JP2003528591A (ja) | 前立腺癌の治療及び診断のための組成物及び方法 | |
| JP2006515749A (ja) | 前立腺癌の治療および診断のための組成物および方法 | |
| JP2003530093A5 (enExample) | ||
| JP2014510519A5 (enExample) | ||
| JP2016513471A5 (enExample) | ||
| JP2017521074A5 (enExample) | ||
| JP2019525764A5 (enExample) | ||
| JP2002524039A (ja) | ヒトアポプトシス阻害剤タンパク質ｈｉａｐ３をコードするｄｎａ | |
| ATE478089T1 (de) | Isolierte polypeptide auf der grundlage des neutralisierenden epitops des p17-proteins vom hiv geeignet als impfstoffe und neutralisierende anti-p17-antikörper, die besagtes epitop spezifisch erkennen | |
| JP2003525566A (ja) | １２５個のヒト分泌タンパク質 | |
| JP2003521216A (ja) | ９０個のヒト分泌タンパク質 | |
| Sanz-Soler et al. | Recombinant expression of mutants of the Frankenstein disintegrin, RTS-ocellatusin. Evidence for the independent origin of RGD and KTS/RTS disintegrins | |
| JP2008531463A5 (enExample) | ||
| US20220340629A1 (en) | Myosin Derived Peptides and Related Compounds with Anticoagulant Activities | |
| ES2258090T3 (es) | Gen humano de tipo wingless. | |
| JP3811733B2 (ja) | Ｄｎアーゼ活性を有する蛋白質 | |
| US9441022B2 (en) | Aegyptin and uses thereof | |
| WO2001038377A1 (fr) | Nouveau polypeptide - la proteine humaine 95 contenant un bromodomaine- et un polynucleotide codant pour ledit polypeptide | |
| JP2018510213A5 (enExample) | ||
| DE60120187T2 (de) | Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen | |
| US7718368B2 (en) | Immunomodulatory protein and useful embodiments thereof | |
| JP2004518410A5 (enExample) | ||
| JP2006516255A (ja) | 治療薬としてのｆ１１受容体（ｆ１１ｒ）拮抗薬 |